MLL-rearranged infant acute lymphoblastic leukemia (ALL) is an aggressive type of leukemia characterized by a unique geneexpression profile. We uncovered that the activation of particular (proto-onco)genes is mediated by promoter hypomethylation. In search for therapeutic agents capable of targeting these potential cancer-promoting genes, we applied connectivity mapping on a gene expression signature based on the genes most significantly hypomethylated in t(4;11)-positive infant ALL as compared with healthy bone marrows. This analysis revealed histone deacetylase (HDAC) inhibitors as suitable candidates to reverse the unfavorable gene signature. We show that HDAC inhibitors effectively induce leukemic cell death in t(4;11)-positive primary infant ALL cells, accompanied by downregulation of MYC, SET, RUNX1, RAN as well as the MLL-AF4 fusion product. Furthermore, DNA methylation was restored after HDAC inhibitor exposure. Our data underlines the essential role for epigenetic de-regulation in MLL-rearranged ALL. Furthermore, we show, for the first time, that connectivity mapping can indirectly be applied on DNA methylation patterns, providing a rationale for HDAC inhibition in t(4;11)-positive leukemias. Given the presented potential of HDAC inhibitors to target important proto-oncogenes including the leukemia-specific MLL fusion in vitro, these agents should urgently be tested in in vivo models and subsequent clinical trials.
Introduction
To date, MLL-rearranged infant acute lymphoblastic leukemia (ALL) remains the most aggressive type of childhood leukemia characterized by a high rate of early relapses and a grim prognosis. 1, 2 This type of leukemia arises from balanced chromosomal translocations involving the Mixed Lineage Leukemia (MLL) gene 3 that appear to develop in utero. 4 Hence, MLL-rearranged ALL is typically diagnosed in infants at or shortly after birth. The most common MLL translocation among infant ALL patients, occurring in about 50% of the cases, is t(4;11) generating the fusion product MLL-AF4 (refs.1,5) as well as, in most instances, the reciprocal fusion product AF4-MLL. 6 Given the importance of the MLL gene in regulating transcription during definitive hematopoiesis, 7, 8 interruptions of MLL lead to abnormal gene expression patterns that presumably favor leukemia development. 9, 10 These unique gene expression profiles are to some extent mediated by leukemia-specific histone modifications, such as histone 3 lysine 79 dimethylation (H3K79me2), established via recruitment of DOT1L by MLL fusion partners. 11 In addition, we recently demonstrated that t(4;11)-positive infant ALL is further characterized by the presence of distinct genome-wide DNA methylation patterns, displaying hypermethylation at multiple gene promoters leading to transcriptional silencing of the associated genes. 12 In the present study, we revisited our DNA methylation profiles and found that, besides vast amounts of hypermethylated genes, a number of genes appeared to be inaccurately hypomethylated. As similar analyses in healthy bone marrow samples revealed that these genes normally remain methylated and suppressed during hematopoiesis, hypomethylation of these genes in t(4;11)-positive infant ALL seems to represent leukemia-specific deregulation of transcription. Moreover, these genes also appeared methylated in pediatric ALL (both infants and older children) lacking translocations of the MLL gene, at levels nearly comparable to normal bone marrow samples, suggesting that hypomethylation of these genes is t(4;11)-specific.
Given this specificity and the fact that multiple hypomethylated genes represented several renowned proto-oncogenes including several MLL-AF4 target genes, 13, 14 we asked whether targeting these genes would have therapeutic potential. In search for compounds capable of targeting various hypomethylated genes at once, we here applied connectivity mapping 15 on a gene expression signature corresponding to the genes most significantly hypomethylated and consequently transcriptionally activated in t(4;11)-positive infant ALL. These analyses and further experiments showed that histone deacetylase (HDAC) inhibitors effectively target t(4;11)-positive ALL cells, mediated or accompanied by downregulation of several proto-oncogenes, including the MLL-AF4 fusion product itself.
Patients and methods

Patient samples
We studied 15 newly diagnosed t(4;11)-positive infant ALL patients (o1 year of age) enrolled in the INTERFANT-99 study (Supplementary Table S1 ). 1 Whole normal bone marrow samples (n ¼ 7) derived from non-leukemic children were used as controls throughout the study. In some instances, pediatric ALL samples (both infants and non-infants) were included as controls to demonstrate t(4;11)-specificity of the hypomethylation. Leukemic cell isolation and enrichment, as well as DNA and RNA extractions were performed as described before 16 without any alterations. Approval for this study and the use of patient material was obtained from the Erasmus MC Institutional Review Board, and informed consent was acquired from parents or legal guardians according to the Declaration of Helsinki.
t(4;11)-positive ALL cell line models
The t(4;11)-positive precursor B-ALL cell lines SEM and RS4;11 were purchased from DSMZ (Braunschweig, Germany). Both cell lines were maintained as suspension cultures in RPMI 1640 with L-Alanyl-L-Glutamine (Invitrogen, Breda, the Netherlands) supplemented with 10% FCS (Integro, Zaandam, the Netherlands), 100 IU/ml penicillin, 100 mg/ml streptomycin, and 0.125 mg/ml fungizone (Invitrogen) at 37 1C in humidified air containing 5% CO 2 .
HDAC inhibitor exposures and MTT assays
HDAC inhibitor exposure experiments were performed by culturing the cell lines SEM and RS4;11 in the presence of 1 mM of Trichostatin A (TSA, Sigma-Aldrich, Zwijndrecht, the Netherlands), 10 mM of Vorinostat (SAHA, Sigma-Aldrich, Zwijndrecht, the Netherlands), 500 nM of Panobinostat (LBH589, Novartis Oncology, Cambridge, MA, USA), 10 mM of Valproic Acid (VPA, Sigma-Aldrich, Zwijndrecht, the Netherlands), 10 ng/ml of Romidepsin (FK228, Celgene Corporation, San Diego, CA, USA) and 10 mM of MS-275 (Sigma-Aldrich, Zwijndrecht, the Netherlands). Cells were sampled after 6, 24 and 48 h of exposure and cell viability was assessed using the trypan blue dye exclusion method. All drug exposures were repeated twice. In vitro HDAC inhibitor cytotoxicity was assessed by 4-day MTT assays, as described earlier. 17 In each cytotoxicity experiment, samples were analyzed in duplicate.
Differential methylation hybridization using CpG island microarrays
Methylation-sensitive restriction enzyme-based Differential Methylation Hybridization (DMH) was performed using 500 ng gDNA and genome-wide CpG island microarrays (Agilent Technologies, Santa Clara, CA, USA) as previously described. 12 Detailed procedures are described in the Supplementary Methods. The genome-wide DNA methylation data has been deposited in the NCBI Gene Expression Omnibus 18 under GEO Series accession number GSE18400 as part of our recently published paper on DNA methylation patterns in MLL-rearranged infant ALL. 12 Gene expression profiling using affymetrix GeneChips Gene expression profiles (Affymetrix (Santa Clara, CA, USA), HGU133plus2.0 GeneChips) were generated for t(4;11)-positive infant ALL cases (n ¼ 15) and healthy pediatric bone marrow samples (n ¼ 7), using the same samples for which DNA methylation profiles were produced. The exact methodology is described elsewhere, 10 and briefly outlined in the Supplementary Methods. The gene expression data was deposited in the NCBI Gene Expression Omnibus 18 under GEO Series accession number GSE 19475 as part of a large gene expression profiling study in infant ALL. 10 
Connectivity map analysis for compound searching
The Connectivity Map (cmap) represents a large collection of gene expression profiles generated in various human cancer cell lines exposed to a broad spectrum of FDA-approved compounds 15, 19 (http://www.broadinstitute.org/cmap/). Using a gene set enrichment metric according to the KolmogorovSmirnov statistic, cmap analysis provides a ranked order of individual treatment instances based on their similarity to a given gene expression profile (or query signature). In the present study, the query signature represents a list of genes that appeared consistently highly expressed as a result of promoter hypomethylation in our selected cohort of t(4;11)-positive infant ALL samples (n ¼ 15). The output of the cmap analysis consists of a list of small-molecule compounds with an assigned gene enrichment metric: the connectivity score. This relative score represents the correlation between the query signature and one of the gene expression profiles of one of the cell lines treated with one of the compounds (as compared with untreated controls). For each cell line separately treated with each compound, connectivity scores are generated, which comprise of both an up-score and a down-score. The down-score (a value between -1 and 1) determines the in silico potential of the associated compound to reverse the query signature under interrogation. Thus, in the present study, a high negative downscore indicates that the corresponding compound is likely to induce downregulation of multiple genes in our query signature. On the basis of the highest negative down-scores, candidate agents were selected for further study.
Quantitative real-time PCR analysis
Total RNA was reverse transcribed and the obtained cDNA was used to quantify mRNA expression by quantitative real-time PCR analysis using the DyNAmo SYBR Green qPCR kit (Finnzymes, Espoo, Finland), as previously described. 20 Primer combinations used for transcript amplification of selected target genes as well as the housekeeping reference gene beta-2-Microglobulin (B2M) are listed in Supplementary Table S2 . Per experiment samples were analyzed in duplicate and all experiments were conducted twice.
Western blot analysis
Western blot analysis for MYC, RUNX1, RAN and SET was performed, as described elsewhere, 16 using a Mini-Trans-blot system (Bio-Rad Life Science Group, Veenendaal, The Netherlands) and the following antibodies: mouse monoclonal anti-c-MYC (Merck, Darmstadt, Germany, #OP30), rabbit polyclonal anti-RUNX1 (Cell Signaling Technology, Danvers, MA, USA #4334), rabbit polyclonal anti-RAN (Cell Signaling Technology Inc., Danvers, MA, USA #4462). Mouse monoclonal anti-SET was kindly provided by Professor Kyosuke Nagata (Tsukuba, Japan). Blots were re-probed with an antiActin mouse monoclonal antibody (Sigma-Aldrich, St Louis, MO, USA #A2547) to confirm equal loading in each lane. For the detection of the MLL-AF4 fusion protein, western blot conditions are slightly different to those described above. Given the predicted size of the MLL-AF4 protein of B270 kDa, medium-sized 5% polyacrylamide gels are required. Proteins are resolved at 60-80 Volt for at least 10-12 h at room temperature. For effective transfer of large proteins to nitrocellulose membranes, the blotting procedure is performed overnight at 41C. Blots are then probed with mouse monoclonal anti-MLL N /HRX (clone N4.4) (Upstate Biotechnology, Temecula, CA, USA #05-764), and the MLL-AF4 protein is visualized using standard procedures. 15 The membrane was re-probed with anti-Clathrin HC (clone TD.1) (Santa Cruz Biotechnology, Middlesex, UK #sc-12734) as a loading control. All western blot analyses were performed at least twice.
Statistical analysis
Data processing and analysis of microarray data were performed as previously described. 10, 12, 21 A P-value of o0.01, corrected for multiple testing by the false discovery rate step-up procedure of Benjamini & Hochberg, 22 was regarded significant. All analyses were performed in R using Bioconductor packages (R Development Core Team, 2007) . Heatmaps were generated in GenePattern version 3.1.1. 23 Differences in proto-oncogene mRNA expression and differences in mean cytotoxic response were evaluated using the Mann-Whitney U-test. Analyses were two-tailed, and differences were considered statistically significant at Po0.01.
Risk of relapse was computed with the Kaplan-Meier estimator. Time to relapse was defined as the time from diagnosis until the date of leukemia relapse or the last follow-up. The log-rank test was used to compare outcomes between different patient groups. SPSS 16.0 statistical software (SPSS Inc., Chicago, IL, USA) was used for computation of survival statistics.
Results
High expression of hypomethylated proto-oncogenes in t(4;11)-positive infant ALL Recently we showed that t(4;11)-positive infant ALL is characterized by severe promoter hypermethylation, 12 which has independently been confirmed by others. 24 However, in our genome-wide DNA methylation analysis the promoters of a subset of protein-coding genes appeared to be significantly hypomethylated in t(4;11)-positive infant ALL (n ¼ 15) as compared with normal pediatric bone marrows (n ¼ 7). Among the most significantly hypomethylated genes (top 200, false discovery rate o0.01), 36 were consistently highly expressed in t(4;11)-positive infant ALL samples, but not in healthy pediatric bone marrows, as determined by gene expression profiling (Figures 1a and b) (Supplementary Tables S3 and S4 ). Moreover, hypomethylation of these genes seemed to be specific for t(4;11)-positive infant ALL, when compared with wild-type MLL infant ALL cases (n ¼ 10) and non-MLL childhood B-ALL cases (n ¼ 10). (Figure 1c ). In conformity with this observation, the t(4;11)-positive ALL cell lines SEM and RS4;11 both uniformly showed hypomethylation and high-level expression for the entire gene list defined in t(4;11)-positive infant ALL patient samples (Figures 1a and b) .
Using the DAVID gene ontology database, 25 we found this gene list to be enriched for proto-oncogenes (P ¼ 0.009) and genes commonly involved in chromosomal translocations in leukemia (P ¼ 0.001) (DAVID enrichment score: 1.84) (Supplementary Figure S1 ). Focussing on the genes described in literature before as potential oncogenes in various malignancies, that is, MYC, HOXA9, SET, RUNX1, RAN, PARK7, DIAPH1 and SFMBT1, quantitative real-time PCR analysis was used to confirm highlevel expression. The expression of all genes was significantly (Po0.01) higher in t(4;11)-positive infant ALL samples (n ¼ 15) than in pediatric whole normal bone marrow samples (n ¼ 7) (Figure 2) . Moreover, these genes were also downregulated in healthy CD19
þ B cells, indicating that epigenetic silencing of these proto-oncogenes is not only common throughout the normal hematopoietic system in general, but also applies to B-cell development in particular. One exception was the Scmlike with four mbt domains 1 gene (SFMBT1) that appeared to be highly expressed in normal CD19
þ B cells despite downregulation in whole bone marrow samples ( Figure 2 ). Therefore, SFMBT1 was excluded from further analyses.
Connectivity map analysis on a t(4;11)-positive hypomethylation-based gene expression profile
Effectively treating MLL-rearranged infant ALL remains one of the major challenges in pediatric hemato-oncology. 26 Therefore, we postulated that the identified list of hypomethylated and highly expressed genes (Figure 1 ), including several known proto-oncogenes, may represent potential targets for therapeutic intervention. As currently no straightforward approaches have been identified to target hypomethylated genes, we set out to indirectly apply connectivity mapping 15, 19, 27 on hypomethylated genes originally identified by high-throughput DNA methylation profiling ( Figure 1 ). The gene-expression signatures available in the connectivity map (cmap) are based on the earlier Affymetrix HGU133A platform, whereas our gene expression data was generated on extended HGU133plus2.0 microarrays, which contain considerably more probe sets. Therefore, it was necessary to eliminate six genes from our original signature because of the absence of corresponding probe sets on HGU133A microarrays. Using the remaining expression profile ( Figure 1d ) as a query signature, cmap analysis was performed. Surprisingly, cmap analysis predicted that the compounds potentially suitable for the purpose of reversing (or downregulating) this hypomethylation-based gene signature, predominantly involved HDAC inhibitors, including repetitive entries for TSA, Vorinostat (or SAHA), VPA, and MS-275 (Supplementary Table S5 , Supplementary Figure S2 ).
HDAC inhibitors effectively target t(4;11)-positive ALL cells
As with most high-throughput analyses using vast data sets, connectivity mapping should at best be considered a hypothesisgenerating tool, which requires further validation. Therefore, we assessed in vitro cytotoxicity in t(4;11)-positive ALL cells induced by these compounds using 4-day MTT assays. For this, six different HDAC inhibitors were selected, including the compounds proposed by cmap analysis, TSA, SAHA, VPA and MS-275, and two additional HDAC inhibitors Panobinostat (LBH589) 28 and Romidepsin (FK228). 29 All HDAC inhibitors were able to eliminate the vast majority of primary t(4;11)-positive infant ALL cells, as well as t(4;11)-positive ALL cell lines ( Figure 3 ). Primary cells from precursor B-ALL patients without MLL translocations (n ¼ 6) were generally less responsive to these agents, especially in case of TSA, LBH589 and FK228.
In most instances, normal bone marrow samples (n ¼ 7) were largely unaffected (in terms of cytotoxicity) or at least demonstrated markedly reduced responsiveness to these drugs ( Figure 3 ).
HDAC inhibitors repress activated proto-oncogene expression in t(4;11)-positive ALL cells
Although HDAC inhibitors effectively induced leukemic cell death in t(4;11)-positive ALL, the question remains whether these effects are indeed mediated or accompanied by downregulation of the genes highly expressed and characterized by promoter hypomethylation. To study this, we exposed the t(4;11)-positive ALL cell lines SEM and RS4;11 to various concentrations of TSA, SAHA, VPA, MS-275, FK228 and LBH589 for 6, 24 or 48 h. During these exposures, cell viability was monitored by trypan blue exclusion (Supplementary Figure  S3) , and mRNA expression was determined using quantitative RT-PCR. Already after 6 h of exposure, at which point no cytotoxicity was yet observed in neither cell line model, RAN, SET, and MYC mRNA expression was notably downregulated to levels comparable with normal bone marrow samples (Figure 4) . After 24 h of exposure RUNX1 was also substantially downregulated in both SEM and RS4;11, whereas HOXA9 and PARK7 mRNA expression remained largely unaffected, or was even increased in response to certain HDAC inhibitors. Remarkably, PKRIR  DIAPH1  DERL1  AUTS2  HS3ST3B1  HOXA9  TOB2   PKRIR  DIAPH1  DERL1  AUTS2  HS3ST3B1  HOXA9  SMEK   BCOR  TCP11L1  INHA  RUNX1  LMNB2  SIAH1  RAN   TOB2  BCOR  TCP11L1  INHA  RUNX1  LMNB2  SIAH1   PKRIR  DIAPH1  AUTS2  HOXA9  TOB2  BCOR  TCP11L1   PSMD11  DPYSL3  SFMBT1  TRIM8  PARK7  HAAO   RAN  PSMD11  DPYSL3  SFMBT1  TRIM8  PARK7  HAAO   INHA  RUNX1  LMNB2  SIAH1  RAN  PSMD11  DPYSL3  PER2  SLTM  SLC30A1  ZCCHC7  ALX4  ICOSLG  GLT8D1  INSM1   PER2  SLTM  SLC30A1  ZCCHC7  ALX4  ICOSLG  GLT8D1   SFMBT1  TRIM8  PARK7  HAAO  PER2  SLTM  ALX4   GTF3C4  GRM2  SET  EIF2AK2  TIAL1  AHCY   INSM1  GTF3C4  GRM2  SET  EIF2AK2  TIAL1  AHCY   GLT8D1  INSM1  GTF3C4  GRM2  SET  TIAL1  AHCY  MYC MYC MYC SMEK -1.5 PKRIR  DIAPH1  DERL1  AUTS2  HS3ST3B1  HOXA9  TOB2  BCOR  TCP11L1  INHA  RUNX1  LMNB2  SIAH1  RAN  PSMD11  DPYSL3  SFMBT1  TRIM8  PARK7  HAAO  PER2  SLTM  SLC30A1  ZCCHC7  ALX4  ICOSLG  GLT8D1  INSM1  GTF3C4  GRM2  SET  EIF2AK2  TIAL1  AHCY Based on its high specificity in targeting t(4;11)-positive ALL cells ( Figure 3 ) and effective downregulation of multiple protooncogenes at the mRNA level (Figure 4) , the HDAC inhibitor LBH589 was selected for further evaluation. Western blot analysis on SEM and RS4;11 cells showed that both MYC and RUNX1 protein expression was substantially downregulated by LBH589 within 24 h of exposure (Figure 5a ). In contrast, the RAN and SET protein expression levels were hardly affected.
Normalized log-ratio of methylation
High expression of proto-oncogenes increases risk of relapse
Next, to further investigate the clinical relevance of high-level expression of the selected proto-oncogenes, we computed survival statistics based on the relative expression obtained from quantitative RT-PCR analysis in a larger group of t(4;11)-positive infant ALL patients (n ¼ 28). The median expression levels were used as cutoff values to divide patients into groups characterized by either high or low proto-oncogene expression. Here, we focused on the genes most responsive to HDAC inhibition at the mRNA level, that is, RAN, RUNX1, SET and MYC. Elevated expression of each gene separately, barely had any influence on the risk of relapse (Supplementary Figures  S4A-D) . However, patients who showed high expression (above the median value from RT-PCR) for 3 or 4 of the protooncogenes (n ¼ 7) had a significantly increased relapse risk (Figure 5b) . Consequently, simultaneous downregulation of 3 or more of these proto-oncogenes, as achieved by, for instance, the HDAC inhibitors TSA, SAHA and LBH589 may well be beneficial for patients otherwise at an extremely high risk of disease relapse. However, because of the low number of patients that could be included in these analyses, these observations must be interpreted with caution or at best be considered preliminary.
LBH589 downregulates MLL-AF4
Noteworthy, when focusing on the genes most responsive to HDAC inhibition both at the mRNA and protein level, both the MYC and the RUNX1 proto-oncogene have been proposed as potential targets of the MLL-AF4 fusion. 13, 14 As it has been reported that HDAC inhibitors are able to abolish the oncogenic fusion proteins AML-ETO and PML-RARa, 30 we here asked whether LBH589 was able to degrade the MLL-AF4 fusion. If so, the here-presented results may need to be interpreted from a different angle as well: do HDAC inhibitors directly downregulate the genes under investigation, or is the suppression of the studied proto-oncogenes a direct consequence of the succumbed expression of MLL-AF4 fusion protein? Interestingly, both at the mRNA and protein level, LBH589 completely neutralized the expression of the MLL-AF4 fusion within 48 h of exposure (Figures 5c and d) .
Increased levels of methylation at proto-oncogene promoters after LBH589 exposure
The identification of the potential of HDAC inhibitors to target aberrantly activated genes in t(4;11)-positive infant ALL was based on specific hypomethylation at the promoters of these genes. As several of these genes indeed were downregulated 
expression levels of the hypomethylated proto-oncogenes (a). DIAPH1, (b). HOXA9, (c). RUNX1, (d). RAN, (e). SFMBT1, (f). PARK7, (g). SET and (h)
. MYC relative to the housekeeping gene B2M. For each gene, relative expression levels were determined in the t(4;11)-positive cell lines SEM, primary t(4;11)-positive infant ALL patient samples (n ¼ 15), normal bone marrow samples (n ¼ 7) and CD19 þ B cells. The P-values correspond to Mann-Whitney U tests comparing the expression levels in t(4;11)-positive infant ALL with the levels observed in normal bone marrow samples. Error bars represent standard errors of the mean (SEM).
Cmap identifies HDAC inhibitors for treatment of MLL-rearranged infant ALL
DJPM Stumpel et al upon exposure to HDAC inhibitors, a final question remains whether transcriptional inactivation of these genes was established by restoration of promoter methylation. To answer this question, we generated genome-wide DNA methylation profiles for the t(4;11)-positive ALL cell line SEM exposed to 500 nM of LBH589 for 0 (controls), 6, 24 or 48 h. Interestingly, upon LBH589 exposure, DNA methylation levels were indeed increased at the promoters of the selected proto-oncogenes (that is, DIAPH1, HOXA9, RUNX1, RAN, PARK7, SET and MYC), although the extent of augmented promoter methylation varied for each of the proto-oncogenes ( Figure 6 ). Nonetheless, promoter CpG methylation of the housekeeping reference gene B2M appeared completely unaltered (Figure 6h) , to some extent, suggesting that LBH589 exposure truly targeted the methylation status of the gene promoters under investigation. However, it should be taken into account that not the methylation status per se was directly targeted by LBH589, but that restored methylation at these gene promoters rather reflects more nonspecific effects. For example, HDAC inhibitor treatment may have specifically killed cells displaying hypomethylation at these loci, while subpopulations of cells bearing methylated gene promoters were more or less spared.
Discussion
Approximately 80% of infants (o1 year of age) diagnosed with acute lymphoblastic leukemia (ALL) carry leukemia-specific balanced chromosomal translocations involving the MLL gene, which represent strong predictors of an adverse outcome, 31 and specify unique gene expression profiles. 9, 10 Wild-type MLL functions as an epigenetic regulator of transcription through histone methyltransferase activity, 32 and is essential for normal hematopoiesis. 7 Specifically, wild-type MLL methylates histone 3 at lysine 4 (H3K4), which embodies an evolutionary conserved histone mark associated with primed gene activation. Reinsuring activated transcription, H3K4 methylation induces an open or active chromatin state, and protects associated loci against DNA methylation at gene promoters to prevent associated genes from transcriptional silencing. Thus, in hematopoietic cells, abrogation of the normal function of MLL on one of the alleles, for example, by chromosomal translocations, potentially leads to an impaired ability to effectuate H3K4 methylation.
14 Despite this apparent loss-of-function, it should be noted that the second MLL allele remains unaffected. Partially losing the ability to methylate H3K4, MLL fusions are now known to recruit an alternative histone methyltransferase, that is, DOT1L, mediating H3K79 methylation. Consequently, H3K79 methylation introduces an extra active histone mark that allows the activation of otherwise inactive genes, presumably in favor of leukemia development. 13, 14 Thus, abnormally overexpressed genes among the gene expression signatures associated with MLL-rearranged leukemias 9 can in part be explained by this mechanism.
Nevertheless, apart from vast amounts of genes characteristically overexpressed in MLL-rearranged infant ALL, at least equal numbers of genes are underexpressed or inactivated. 10 Recently, we demonstrated that one mechanism responsible for 
) (a). TSA, (b). SAHA, (c). LBH589, (d). VPA, (e). FK228, (f). MS-275. Error bars represent standard errors of the mean (SEM)
. Differences in mean cytotoxicity between patient cells and normal bone marrow cells were statistically analyzed using the Mann-Whitney U-test and differences were considered statistically significant at Po0.01.
gene inactivation in MLL-rearranged infant ALL involves epigenetic silencing through gene promoter hypermethylation.
12
The latter is especially true in patients carrying the most common MLL translocation t(4;11), producing the MLL-AF4 fusion protein, and, as recently reported, in most instances, also the reciprocal fusion product AF4-MLL. 6 In the present study, we revisited our genome-wide DNA methylation profiles 12 and found that in t(4;11)-positive infant ALL numerous genes are also hypomethylated and, consequently, highly expressed. As these genes remained hypermethylated and silenced in normal hematopoietic cells, the loss of suppressive promoter methylation and consequent activation of transcription of these genes in t(4;11)-positive ALL may well have been involved in the transformation process. Supporting this assumption, these genes frequently involve potential proto-oncogenes, like MYC, and DIAPH1. 40 Moreover, several of the hypomethylated genes that we identified in this study, that is, ZCCHC7, HOXA9 and MYC, have all been shown to be activated by the MLL-AF4 fusion itself via H3K79 methylation through the recruitment of DOT1L. 13, 14 This observation indisputably illustrates interactions between DNA methylation and histone modifica- 
a). RAN, (b). SET, (c). MYC, (d). RUNX1, (e). HOXA9, (f). PARK7 and (g). DIAPH1
relative to the housekeeping gene B2M. mRNA expression levels were determined in the t(4;11)-positive cell lines SEM (A) and RS4;11 (B) exposed for 6 h to different concentrations of the six HDAC inhibitors TSA (1 mM), SAHA (10 mM), LBH589 (500 nM), VPA (10 mM), FK228 (10 ng/ml) and MS-275 (10 mM). For RUNX1, PARK7, DIAPH1 and HOXA9 data after 24 h exposure are presented as well (hatch fill). Expression levels in s.e.m. or RS4;11 were set to 100%.
tion in regulating gene expression. Apparently, MLL fusion protein-driven H3K79 methylation, leading to an open and active chromatin state, is frequently accompanied by the release of transcriptional suppressive promoter methylation at associated genes. From this perspective, our finding that HDAC inhibitors seemed to be particularly suitable to downregulate aberrantly hypomethylated and highly expressed proto-oncogenes in t(4;11)-positive ALL cells seems rather unexpected and even counterintuitive. HDAC inhibitors are believed to induce transcriptional reactivation of dormant gene loci, by suppressing histone deacetylases and allowing active chromatin states. At the same time, the full spectrum of the effects of these compounds, which often are nonspecific and off-target, and the exact mechanisms through which these agents act, remain poorly understood. Although the here-presented effects of various HDAC inhibitors on a specific set of hypomethylated proto-oncogenes seem to fall into the category of nonspecific, yet highly favorable drug actions, this may be debated. of the MLL-AF4 fusion by HDAC inhibition may thus have led to impaired H3K79 methylation, rapidly resulting in the inactivation of these specific proto-oncogenes as well. Yet, not all of the genes in our hypomethylated signature represent known MLL-AF4 target genes. This suggests that the downregulation of these genes may not have been influenced by the degradation of MLL-AF4 directly, but may have been repressed indirectly as a result of direct suppression of their regulators. In any case, the possible involvement of MLL-AF4 degradation in downregulating hypomethylated proto-oncogene expression immediately imposes another question: how does HDAC inhibition mediates the neutralization of the MLL fusion? Obviously, this phenomenon again is counterintuitive and a possible mechanism remains obscure, although important clues may already have been published. For example, Xia et al. (2003) , showed that the MLL repression domain, which is retained in MLL fusions and postulated to be required for transforming activity, interacts with histone deacetylase 1 (HDAC1) and partially mediates its activity. 41 Thus, HDAC inhibition may well disrupt this interaction and compromise vital functions of the MLL fusion or, perhaps, its stability. On the other hand, this may explain degradation of MLL-AF4 at the protein level, but not its suppression at the mRNA level.
Whether or not proto-oncogene downregulation by HDAC inhibitors is directly mediated by degradation of the MLL fusion or involves other (yet to be elucidated) mechanisms, the expression of several of the proto-oncogenes may have important clinical implications. Of specific interest are the proto-oncogenes that did display rapid responses at the mRNA level, that is, RAN, SET, MYC and RUNX1, and in case of MYC and RUNX1 at the protein level as well. In contrast to MYC, which seems to promote transformation predominantly by stimulating cell proliferation, 33 the RUNX1 proto-oncogene seems to affect differentiation. RUNX1 is believed to be required in development during the endothelial to hematopoietic cell transition only, and not thereafter. 42 However, to date, this has only been shown in mice, and a similar dependence in humans remains to be established. Nonetheless, it may be plausible that RUNX1 expression could not have been repressed during lymphoid differentiation in t(4;11)-positive infant ALL cells. The fact that t(4;11)-positive ALL blasts characteristically resemble highly immature, CD10-negative, precursor B cells, implies that the inability to downregulate RUNX1 at this stage may indeed have blocked differentiation. Moreover, amplification and over-expression of RUNX1 has been associated with a poor prognosis in childhood precursor B-cell ALL in general, 43 further emphasizing its potential oncogenic role in developing B cells. Interestingly, it has been proposed that full oncogenic transformation by RUNX genes can only be accomplished in close collaboration with genes that rescue cell proliferation, such as MYC. 36 Therefore, the concerted upregulation of both MYC and RUNX1 in t(4;11)-positive infant ALL may not at all be a coincidence. MYC protein in addition may be regulated by several mechanisms including different ubiquitinylation patterns that may lead to destruction or survival of the protein. 44 Through the identification of high-level expression of this particular set of known proto-oncogenes, and the abovesuggested link between MYC and RUNX1, we here obviously touch upon the principle of 'oncogene cooperation' already described by Weinberg and co-workers in 1985. 45 Reflecting such a mechanism of oncogene cooperation in t(4;11)-positive ALL is our data showing an extremely high risk of relapse in patients firmly overexpressing three or more of the hypomethylated proto-oncogenes. However, these data must be interpreted cautiously, because a multivariate analysis could not be performed because of low patient numbers. Targeting these proto-oncogenes, for example, using HDAC inhibitors, may thus be a vital step in taming the aggressiveness of this malignancy. Figure 6 Increased methylation at specific gene promoters after exposure to LBH589. DNA methylation levels from array-based DNA methylation profiling were determined in the t(4;11)-positive cell line SEM exposed for 6, 24 or 48 h to HDAC inhibitor LBH589 (500 nM).
Methylation levels of the proto-oncogenes (a). DIAPH1, (b). HOXA9, (c). RUNX1, (d). RAN, (e). PARK7, (f). SET, (g). MYC and (h)
. B2M relative to the unexposed cell line (SEM blanc) are presented. Fold-change of methylation is presented on the y axis and methylation levels in SEM blanc were set to 1.
Yet, the keynote of this study should unquestionably be the opportunity for therapeutic intervention targeting the MLL-AF4 fusion itself. Given the tremendous cytotoxic effects of all HDAC inhibitors tested on primary t(4;11)-positive infant ALL samples in vitro, these data demand further studies evaluating HDAC inhibition in in vivo models 6 and subsequently in a clinical setting. Emphasizing this statement, most of the HDAC inhibitor concentration used in our 4-day MTT assays that appeared sufficient to eliminate the vast majority of t(4;11)-positive infant ALL cells in vitro, resemble clinically achievable and tolerable plasma concentrations in various clinical trials. For example, in our in vitro data 0.5-1 mM of Vorinostat (SAHA) showed maximum cytotoxic effects in t(4;11)-positive infant ALL cells, whereas plasma concentrations of 2.5 mM are easily exceeded in patients with relapsed lymphoma intravenously or orally treated with 75-900 mg/m 2 daily. 46 Similarly, in a phase II trial in patients with Tcell lymphoma treated with Romidespin (FK288), plasma concentrations were achieved ranging from 300-400 ng/ml 47 whereas the present study shows that concentrations of 1-10 ng/ml are sufficient to kill the majority of t(4;11)-positive ALL cells in vitro. Finally, plasma levels in patients with refractory hematologic malignancies intravenously treated with LBH589 easily reached 120-560 ng/ml 48 while in our in vitro data LBH589 concentrations of 20 -50 ng/ml seem more than adequate. In addition and further accentuating the potential of HDAC inhibition in MLLrearranged leukemia, Burbury and co-workers recently published a case report in which they describe the successful treatment of a 60-year-old patient suffering from MLL-rearranged leukemia who sustained a complete cytogenetic response to single-agent HDAC inhibitor treatment. 49 On the basis of the present observations demonstrating the potential of HDAC inhibitors, and recent findings from our laboratory showing the potential of demethylating agents, 12 we conclude that MLL-rearranged infant ALL patients would greatly benefit from treatment regimens including (combinations of) various epigenetic drugs.
